Scenario wins: Mantic (63) pgodzinbot (59) lewinke-thinking-bot* (34) AtlasForecasting-bot (17) cassi (14) SynapseSeer (10)
| Figure/Metric | Value | Source | Significance |
|---|---|---|---|
| IPO Issue Price | €25.00 | Euronext / Wikipedia | Original valuation benchmark from January 2026. |
| Recent Closing Price | €15.28 | Investing.com (11 May 2026) | Baseline price level just before the forecast window. |
| 2025 Order Backlog | €15 Billion | CSG FY 2025 Statement | Provides ~2.2 years of revenue visibility. |
| 2026 Revenue Guidance | €7.4 - €7.6 Billion | CSG Annual Report | Implies a 10-13% growth rate vs 2025. |
| Annualized Volatility | 65.5% | Yahoo Finance | Indicates extreme price uncertainty and potential for sharp bounces. |
| RSI (14-day) | 27.09 | Equity Deep Dive | Suggests the stock is in ‘oversold’ territory. |
The question asks for the maximum daily closing price of CSG on Euronext Amsterdam during the 27 trading days from 1 Jul–7 Aug 2026. Forecasters agree the mechanical price-action baseline—using ~50 daily closes and a Monte‑Carlo random‑walk with a modest negative drift (μ≈‑0.5% and σ≈4.6%)—puts the median window maximum in the mid‑teens (p50 ≈ €15; baseline quantiles p05≈€9, p25≈€12, p75≈€20, p95≈€24–27). All teams flag the Hunterbrook short‑report episode (capacity, a €275m receivable) as a key credibility overhang and identify the 20 May Q1 release and the H1 results on 7 Aug (the last eligible day) as decisive catalysts that could widen tails sharply. Scenario mixes typically allocate most mass to a bear/base-stabilisation outcome (combined ≈50–75%), a meaningful recovery tail to mid/late‑20s if Q1/H1 reassure, and a small but non‑negligible chance of >€30 (roughly 5–9%) versus a low‑probability severe collapse below €8 (≈1–3%). Other relevant technical/contextual factors cited: analyst targets clustered ~€31–42 (likely stale), a company lock‑up expiry around 26 Jul that could add mild downward pressure, and strong sector beta but company‑specific idiosyncrasy. In short, the consensus median expectation is a maximum in the mid‑teens, with asymmetric fat tails driven chiefly by Q1/H1 news and short‑seller credibility outcomes.
Forecast: Probability distribution:
We are forecasting the highest official daily close (not the end-of-window price) of CSG on Euronext Amsterdam during 1 Jul–7 Aug 2026 (~28 trading days), from a starting point where (per analysts’ cited quotes and Reuters context) the stock is in the mid-teens in early May after a >50% drawdown from the €25 IPO price and a sharp drop on 4 May following a short-seller report.
Key drivers for the maximum close in the window:
Across the three analyst forecasts, Forecasters 2 and 3 are broadly consistent (median max close ~€18–€19; p95 below €30), while Forecaster 1 is more optimistic (median €21 and puts some mass >€30). I weight 2 and 3 more heavily because they explicitly adjust for the “maximum-in-window” quantity and calibrate to recent trading ranges, but I still include a modest chance of a sharp rebound spike given the stock previously traded in the mid/high-20s post-IPO.
Net: a central estimate for the maximum close is around €19–€20, with a meaningful upper tail into the high-20s, and a small but non-trivial chance (~single-digit %) that an exceptional rebound produces a close above €30 during the window (represented by p95 > 30).
A typical amateur approach would anchor on the current spot price or attempt to guess the Aug 7 close, underestimating the asked quantity because the resolution is the maximum close over many sessions. This forecast improves by (1) explicitly incorporating the max-over-~28-trading-days effect, (2) pooling multiple calibrated analyst distributions rather than relying on a single narrative, and (3) representing tail risk from discrete news (both further downside and a rebound spike) without overconcentrating probability at the bounds. Confidence is moderate: the main uncertainty is event-driven (news/catalysts), not day-to-day noise.
Forecast rationale (numeric):
— Iteration 1 — Across the forecasts, the shared view is that the stock starts the window in the mid-teens and that, over a 5–6 week period, the highest daily close is likely to end up somewhat above that baseline, but not dramatically higher under normal conditions.
The forecasts collectively describe a stock that is volatile enough to produce a meaningful short-term high, but where the expected maximum closing price remains in the high teens, with the distribution widened by event-driven uncertainty and a small probability of extreme upside or downside.
— Iteration 2 — Across the reasoning, the forecast is anchored to Czechoslovak Group’s mid-teens EUR share price in early May 2026 and treats the July–early August window as a short, highly volatile period in which the key quantity is the maximum daily closing price, not the average price.
The collective view is that the highest official daily close in the period will most likely be modestly above the mid-teens starting level, probably landing around €19, but with substantial uncertainty because the stock is volatile and event-driven. The forecasts agree that extreme outcomes in either direction are possible, though the center of mass is clearly in the high teens to low twenties.
— Iteration 3 — Across the forecasts, the main reasoning is that the July–early August figure should be treated as the maximum of many daily closes, not a typical end-of-period price. That mechanically pushes the expected value above the starting level because even a moderately volatile stock has a decent chance of producing at least one higher close over roughly 4–6 weeks.
Overall, the forecasts imply that the highest official daily close in the window will most likely be above current trading levels but below the historical peak, with the central outcome around €18–€22 and substantial uncertainty driven by the company’s event risk and elevated volatility.
Here is a synthesis of the qualitative reasoning shared across the 10 rationales:
1. Context and Historical Base Rates Forecasters universally ground their assessments in the recent extreme drawdown of Czechoslovak Group (CSG) shares, which was catalyzed by a broader cooling in the European defense sector and sharply accelerated by a prominent short-seller report. The rationales agree that the historical base rate for newly public companies recovering from >50% short-seller-induced drops is highly unfavorable. Rapid “V-shaped” recoveries are exceptionally rare; instead, targeted stocks typically suffer from a prolonged “trust discount,” leading to stagnation or continued downward drift as institutional investors wait for audited clarity.
2. The Mathematics of the “Highest Close” A crucial, universally agreed-upon point is the mathematical skew introduced by the question’s resolution criteria. The prompt asks for the maximum daily closing price over a volatile 5-week window, not the median or average price. Because CSG currently exhibits extreme implied and realized daily volatility, statistical random walk principles dictate that the highest price achieved during this window will inherently sit significantly above the stock’s average trading price. Even in a sideways or bearish scenario, natural intraday and daily volatility spikes pull the expected maximum upward.
3. Major Upside Catalysts and Squeeze Potential Despite the bearish base rates, the rationales highlight several strong fundamental and macroeconomic factors that could trigger sudden upward spikes:
4. Structural Headwinds Counterbalancing the upside catalysts is the impending 180-day IPO lock-up expiration, which lands exactly in the middle of the resolution window. Forecasters note that the anticipation of millions of previously restricted shares becoming eligible for sale traditionally exerts heavy downward pressure on a stock. Because of this, several rationales theorize that the highest price in the window is likely to be set early in July, prior to the lock-up expiration taking its toll on the share price.
Summary Ultimately, the forecasters balance the heavy, historically proven anchor of short-seller skepticism and lock-up expirations against the upward convexity of forecasting a “maximum” price in a volatile, highly-subsidized defense sector. The resulting consensus expects high volatility to drive a notable peak, heavily dependent on the company’s ability to clear its name during impending earnings calls.
Agent Forecast (numeric, confidence: low)
Base Rate: Historical European IPO lockup expiry studies generally show 5-15% price pressure around the release date, with greater impact when insider holdings are concentrated (84.8% here is extreme). Combined with ~4-6% observed daily volatility over a ~27-trading-day window, the maximum closing price is typically 10-25% above the period average (lower end of range due to overhang). With the stock at €15.40 on May 11 and expecting it to trade in a €13-17 average range during the window, the highest closing price most likely falls in €15-19, with right-tail risk to €22+ on H1 results beat and left-tail risk to €10-12 on lockup-driven selling.
Initial Reasoning:
Key Uncertainties:
Evidence Sources (11):
Grounding Facts (passed to reviewers):
Draft: 16.3-19: 22.0%, 19-21.8: 19.0%, 13.5-16.3: 18.0%, 21.8-24.5: 13.0%, 10.8-13.5: 9.0%
Reviewer Panel:
Reviewer (reasoning)
The analysis leans heavily on optimistic analyst targets and the H1 results catalyst without grounding in base‐rate evidence, notably underestimating the downward pressure from a large lockup expiry and muted summer liquidity. It also fails to adjust 12-month price targets for their known positive bias or account for the mismatch between a multi‐month target and a 5-week event window. The typical share price reaction to 180-day lockup releases and comparative defense IPOs is ignored, leaving a major gap in the upside/downside assessment. As a result, the 2% chance of a >€30 closing seems substantially overstated.
Objections:
Reviewer (calibration)
The draft forecast significantly underweights the potential negative impact of the 180-day IPO lockup expiry for the controlling shareholder’s ~84.8% stake. This massive potential supply coming onto the market around July 21st could easily cap any upside from positive H1 results or even drive prices further down. Additionally, the reliance on analyst BUY ratings and high price targets seems disconnected from the recent price action and negative sentiment following the short-seller report and broader market reactions to peace talks.
Objections:
Reviewer (fact-checker)
1 factual error(s). 1 unsupported claim(s). Verdict: minor_issues
Unsupported claims:
Objections:
Adjustment Rationale:
Shifted ~6 points of probability from upper bins (€19+) down to middle-lower bins (€13.5-€19) to address the calibration and reasoning reviewers’ valid concerns. (1) The ~July 21 lockup expiry for the controlling shareholder’s ~84.8% stake falls mid-window and creates a structural overhang that typically suppresses prices 5-15% around the date and caps relief rallies — my draft underweighted this. (2) 12-month analyst targets (avg €35.40) are biased upward and not directly applicable to a 5-week window high, so I reduced their anchoring effect on the upper bins. (3) July-August summer seasonality reduces volume and dampens extreme moves, modest negative for tail upside. I kept a small upside tail (>€21.8) because the H1 2026 results release (likely late July, after the July 8 quiet period) is a genuine single-day spike catalyst that lockup overhang would not fully neutralize. Downgraded confidence from medium to low given unquantified lockup magnitude and unknown Q1 earnings outcome (May 19, before window). The fact-checker’s note on calendar vs. trading days is acknowledged but doesn’t change the framework.
forecast_sdk | 525.6s | research $0.8221 + reviewers $0.0126 + reconcile $0.1550 = $0.9897
Extracted Percentile Values: {0.1: 7.4, 1.0: 9.1, 5.0: 11.7, 10.0: 13.1, 15.0: 14.4, 20.0: 15.5, 25.0: 16.5, 30.0: 17.4, 35.0: 18.3, 40.0: 19.1, 45.0: 19.8, 46.0: 19.9, 47.0: 20.0, 48.0: 20.2, 49.0: 20.3, 50.0: 20.5, 51.0: 20.7, 52.0: 20.9, 53.0: 21.1, 54.0: 21.3, 55.0: 21.5, 60.0: 22.1, 65.0: 22.9, 70.0: 23.9, 75.0: 24.9, 80.0: 25.8, 85.0: 27.2, 90.0: 29.0, 95.0: 31.2, 99.0: 35.0, 99.9: 39.0}
Model’s Answer: Step one is to anchor on the exact thing being forecast: the highest official daily closing price during 1 July to 7 August 2026, not the end-of-window price and not any intraday high. That matters because CSG is a high-volatility stock; over a month-long window, the maximum close is usually meaningfully above the contemporaneous spot price even if the average path is flat or slightly down.
Step two is to weight sources by relevance and recency. The most important inputs are the official Euronext/Yahoo daily close history and the recent Reuters/Bloomberg reporting on the May 4 short-seller shock. Those tell me CSG is now around 15.4 to 15.8, down sharply from the 25 IPO and far below the post-IPO 35.5 high, with very large daily moves. Company guidance, backlog, and bullish analyst targets matter, but I discount them somewhat because they are partly narrative and partly backward-looking. The strongest structural positive is still the European defence-spending boom and CSG’s large ammunition footprint. The strongest structural negative is that this is now a “broken IPO” with credibility damage, leverage concerns, and unresolved execution questions.
Step three is to translate that into a distribution for the maximum close in the July-August window. If nothing especially new happens, a stock sitting around the mid-teens in May, with this kind of volatility, can easily print a highest close in the high teens or low 20s over a later 28-trading-day span. That base effect pushes the median above today’s price. On the other hand, a full recovery to the IPO price or above requires more than just normal volatility; it likely needs at least one clear catalyst such as a reassuring May 20 trading update, continued contract wins, a sector-wide defence rally, or a squeeze after the short report loses traction.
My central view is therefore “partial recovery / volatile stabilization,” not “continued collapse” and not “fast round-trip back to the IPO.” I put the median highest close around 20.5. I keep a meaningful right tail because the question asks for the maximum close and because August 7 H1 results fall inside the window. I keep a meaningful left tail because broken post-IPO names can keep de-rating, and if the short thesis gains credibility the stock could spend the whole window well below current levels.
The assumptions that matter most are these. First, I’m assuming Hunterbrook’s claims do not turn into a materially worse governance or capacity story; I’d put failure of that assumption around 25%. Second, I’m assuming management communications through May and into summer are at least good enough to prevent a fresh step-function de-rating; failure around 30%. Third, I’m assuming the European defence equity backdrop remains broadly constructive rather than turning sharply risk-off; failure around 25%. Those failure modes are what create most of the left tail.
A low outcome would come from another serious trust hit: evidence supporting the short thesis, weaker-than-expected operating data, or a broader market selloff that compresses defence valuations. I see roughly a low-teens probability that the highest close is below 14, and only around 1% that it is below 9 to 10. A high outcome would come from the opposite combination: the short thesis fading, guidance holding, backlog and contracts being validated, and momentum/speculative buyers pushing the name back toward peer-style defence multiples. I see roughly a bit over 10% chance that the highest close exceeds 28, and about 1% chance it exceeds the old 35.5 high.
Percentile .1: 7.4 Percentile 1: 9.1 Percentile 5: 11.7 Percentile 10: 13.1 Percentile 15: 14.4 Percentile 20: 15.5 Percentile 25: 16.5 Percentile 30: 17.4 Percentile 35: 18.3 Percentile 40: 19.1 Percentile 45: 19.8 Percentile 46: 19.9 Percentile 47: 20.0 Percentile 48: 20.2 Percentile 49: 20.3 Percentile 50: 20.5 Percentile 51: 20.7 Percentile 52: 20.9 Percentile 53: 21.1 Percentile 54: 21.3 Percentile 55: 21.5 Percentile 60: 22.1 Percentile 65: 22.9 Percentile 70: 23.9 Percentile 75: 24.9 Percentile 80: 25.8 Percentile 85: 27.2 Percentile 90: 29.0 Percentile 95: 31.2 Percentile 99: 35.0 Percentile 99.9: 39.0
Forecast: median = €20.1374
Starting Price Impact: The price level at the beginning of the window is crucial, influenced by upcoming Q1 earnings and sector dynamics. A higher starting price can significantly elevate the maximum closing price achievable during the window.
Short-Seller Controversy: The resolution of allegations against Czechoslovak Group will heavily influence stock performance. Positive outcomes could lead to a sharp price increase, while negative developments may suppress it.
Sector Sensitivity: The stock’s performance is closely tied to the European defense sector’s trajectory, particularly regarding geopolitical events like the Russia-Ukraine situation. Continued conflict could bolster prices, while a ceasefire might have the opposite effect.
High Volatility: The stock exhibits substantial volatility, which suggests that even a modest upward movement in price could lead to significant spikes in the maximum closing price during the 27-session window.
Scenario Analysis: Various potential scenarios, ranging from continued deterioration to strong recovery, indicate a wide range of possible outcomes. The weighted average of these scenarios supports a forecast that reflects both upside potential and downside risks.
Market Sentiment: Analyst targets remain high despite recent declines, indicating that there is still considerable optimism about the company’s long-term prospects, which could influence trading behavior leading into the resolution window.
Forecast (percentiles, aggregated):
Per-model forecasts:
Rationale: Summary Czechoslovak Group (CSG) shares have experienced severe volatility since their January 2026 initial public offering. Initially priced at €25 and reaching highs of approximately €35.50, the stock entered a steep decline, trading in the €15.40 to €15.80 range by early May 2026. This downward momentum was heavily exacerbated by a May 4 short-seller report from Hunterbrook Capital, which prompted a 13% single-day drop. Despite this negative sentiment, fundamental defense industry tailwinds remain strong, and analyst consensus continues to indicate “Buy” ratings with average target prices near €35.40. Because the estimate requires the absolute highest closing price over an approximately 27-trading-day window, the baseline expectation naturally sits above the prevailing average price. The median estimate of €18.1 envisions a stabilization and partial recovery, fueled by the fact that the company’s H1 2026 earnings release on August 6 falls directly within the resolution window, offering a prime catalyst for a sharp, transient peak.
Strongest Arguments for Higher Values
Strongest Arguments for Lower Values
Key Uncertainties
As of Monday, May 11, 2026, CSG is trading from a much lower base than at IPO. Euronext says the shares were issued at €25 on January 23, 2026; by May 11, MarketScreener showed CSG around €15.39 intraday, with a May 8 close of €15.78, a one-month range of €13.62-€22.83, and moving averages of €19.92 over 20 days and €24.81 over 50 days. That combination tells me the stock is both heavily derated and still very volatile. (euronext.com)
Fundamentally, the business still looks strong. In FY2025 CSG reported €6.741 billion of revenue, €1.626 billion of adjusted operating EBIT, a 24.1% adjusted operating EBIT margin, €15 billion of backlog and a €27 billion pipeline, while reaffirming FY2026 guidance of €7.4-€7.6 billion of revenue and an adjusted operating EBIT margin of about 24-25%. Net debt was €3.004 billion, or 1.7x LTM adjusted operating EBITDA, and the company said Moody’s upgraded its backed senior secured debt to investment-grade Baa3 in February 2026. Those numbers make a total collapse less likely unless the market decides the disclosures themselves are unreliable. (live.euronext.com)
Operationally, CSG has kept announcing contract wins and capacity expansion. It disclosed a nearly €250 million long-range 155 mm ammunition contract on April 23, and in its May 5 rebuttal said 2025 own-production capacity was about 630,000 rounds, that 2026 own-production should rise by roughly 20%, and that medium-term own production is guided to 1.1 million rounds. It also said the €275 million related-party receivable criticized by Hunterbrook was fully settled in Q1 2026. These points matter because if investors believe them, the stock can rebound sharply from depressed levels. (live.euronext.com)
But the bearish case is real. Reuters reported a 13% one-day drop on May 4 after Hunterbrook’s short report, and CSG’s own initial response shows management felt compelled to issue same-day and next-day rebuttals. More broadly, Reuters also reported on April 20 that European defence stocks had cooled as investors questioned stretched valuations and how future wars will be fought, even while the long-term spending backdrop remained supportive. So I do not think it is enough to extrapolate from backlog and analyst targets alone. (sahmcapital.com)
Valuation and sell-side views give upside room but not a short-term destination. At around €15-16, MarketScreener showed CSG on about 14.8x 2026 estimated earnings and 2.29x 2026 EV/sales, while Investing.com showed an average 12-month analyst target of €35.40 and J.P. Morgan initiated with Overweight and a €40 target. I treat those as evidence that the stock can trade materially above the mid-teens if confidence returns, but because this question resolves in just a little over five weeks of trading, I discount those 12-month targets heavily. (marketscreener.com)
The timing is unusually important. CSG’s Q1 2026 results are due on May 20, 2026, well before the window, so July 1 should already reflect the market’s first post-IPO hard look at numbers. During the window itself, the company calendar shows a half-year report on July 28, 2026, which is the main upside or downside catalyst. Separately, IPO reporting said the selling shareholder was subject to a 180-day lock-up and that the owner still controlled about 85% after listing, which I infer creates an overhang around roughly July 22, 2026, just before the half-year report. That lock-up-expiry risk is a key reason I center the forecast well below analyst targets. (live.euronext.com)
My model is therefore a four-regime mixture for the window-high itself: a bearish regime where the short thesis or lock-up overhang dominates; a base regime with partial mean reversion; a bullish regime where Q1/H1 validate guidance and the stock re-rates toward the low-20s; and a small squeeze/re-rating tail. Because the question asks for the maximum close during the window rather than the final close, I lift the central estimate above my expected ordinary trading level for late July and early August. The resulting distribution has a median around €19.7, a mean around €20.1, roughly a 10% chance of exceeding about €25.5, and about a 3% chance of exceeding €30. In words: I expect some rebound from the current depressed price to be more likely than a fresh collapse, but not a full return to the post-IPO euphoric zone by early August. (marketscreener.com)
CSG priced its IPO at €25 per share in January 2026, and Reuters reported the stock closed 31% higher on its debut. But the more relevant starting point for this question is the subsequent derating: StockAnalysis shows closes of €25.72 on March 26, €23.39 on March 27, €18.42 on April 30, €16.00 on May 4, and €15.78 on May 8. So I am forecasting a stock that entered May in a clear downtrend, not one still trading on pure IPO euphoria. (omni.se)
Fundamentally, company disclosures still look strong. In its FY 2025 results statement, CSG reported €6.7bn of revenue, €1.6bn of adjusted operating EBIT, a €15bn backlog, and a €27bn pipeline, while reaffirming FY 2026 guidance for €7.4-7.6bn of revenue and an adjusted operating EBIT margin of about 24-25%. Management also explicitly tied demand to elevated defence budgets and a record backlog. That combination makes a rebound from the panic lows plausible, even if not assured. (live.euronext.com)
The event calendar is crucial. CSG says Q1 2026 results are due on May 20, 2026, and the company IR site lists Half Year 2026 Results for August 7, 2026, which is the final day of the resolution window. That means the highest close in the window could easily be set on an earnings-driven re-rating on the last day. (live.euronext.com)
I do not treat the Hunterbrook short report as decisive either way. Reuters reported the 13.1% May 4 drop and said the shares were down more than 50% since the IPO. In its formal rebuttal, CSG said Hunterbrook mischaracterized its business model and disclosures; CSG said 2025 own-production capacity was about 630,000 rounds, 2026 own-production would rise by roughly 20%, and the €275m related-party receivable had been settled in full in Q1 2026. Those points create a believable rebound path if Q1 and H1 results support management’s case, but the pre-existing downtrend means the market’s concerns are broader than a one-day short attack. (sahmcapital.com)
There is also meaningful positive operational news behind the name. In April, CSG announced nearly $2.5bn of air-defence contracts in Southeast Asia, a further artillery-ammunition contract worth almost €250m, and an expansion of European ammunition capacity through the Hirtenberger Defence Systems stake. Yet the share price still kept falling into early May. I read that as evidence that order wins support the floor under fundamentals, but that valuation repair probably requires hard reassurance on governance, capacity, and cash-conversion questions rather than more headline contract announcements alone. (live.euronext.com)
One modestly bullish structural point is supply overhang. The prospectus says the Company agreed to 180-day restrictions after settlement, while the Selling Shareholder and certain directors agreed to 360-day restrictions after settlement. So I do not expect a large controlling-shareholder unlock to hit during the July 1 to August 7 window. (ir.czechoslovakgroup.com)
My forecast therefore uses a mixture distribution over the maximum close itself, not just the end-of-window close. The scenarios are: a bearish case where the short thesis keeps dominating and the stock stays in the low-to-mid teens; a base case where Q1/H1 are good enough to stabilize the story and the stock trades back into the low 20s; a bullish re-rating case where management largely clears the overhang and the shares revisit the mid-to-high 20s; and a small squeeze/re-rating tail above €30. This gives a median a little above €21, most mass between roughly €13 and €29, about a 9% chance that the highest close exceeds €30, and about a 0.5% chance that it never gets above €8.
My median forecast for the highest official daily closing price of CSG shares on Euronext Amsterdam between July 1, 2026 and August 7, 2026 is €21.01.
I start from where the stock actually is. CSG listed on Euronext Amsterdam on 23 January 2026 at €25 per share, raising €3.8 billion and representing 15.2% of issued share capital. The shares then closed their debut at €32.85, were still at €33.01 on 27 January, and later closed at €32.56 on 9 March before sliding to €25.00 on 1 April and 8 April, €21.34 on 23 April, €16.00 on 4 May, and €15.78 on 8 May; Investing also showed about €15.38 intraday on 11 May and a 52-week range of €13.62 to €35.50. So the question is not whether the stock can move a lot; it already has. The question is whether it can stage a partial recovery by the 1 July to 7 August window, and how far that rebound can run at its best close. (live.euronext.com)
The immediate reason for the latest collapse is clear. Reuters reported that CSG fell 13.1% on 4 May, its worst day since the IPO, after a Hunterbrook short report challenged the company’s business model, production capacity, and governance; Reuters also said the stock had fallen by more than 50% from the January IPO by then. CSG’s 5 May response rejected the allegations, said the €275 million related-party receivable had been settled in full in Q1 2026, reiterated its 2026 production-capacity guidance, and said the order book remained strong. That leaves the stock in a classic credibility gap: fundamentals still look strong on paper, but a meaningful part of the market no longer trusts them without more proof. (tradingview.com)
On the bullish side, the company’s reported operating backdrop is still powerful. In its FY2025 results, CSG reported €6.7 billion of revenue, €1.6 billion of adjusted operating EBIT, a €15 billion backlog, and a €27 billion pipeline under negotiation. Management reaffirmed FY2026 guidance for €7.4-7.6 billion of revenue and roughly 24-25% adjusted operating EBIT margin. If investors come to believe those numbers and guidance are substantially real, a share price in the mid-teens looks very compressed relative to the business. (live.euronext.com)
Timing is crucial because there are two major reporting catalysts around this forecast horizon. CSG’s IR calendar shows a Q1 2026 trading update on 20 May and Half Year 2026 results on 7 August, with a quiet period from 8 July. Also, the FY2025 results were released at 07:21 CET on 26 March, before the Amsterdam cash equity session. I therefore infer that there is a meaningful chance the 7 August H1 release will affect the 7 August closing price itself, which matters because 7 August is the final day of the resolution window. This slightly fattens both tails of the distribution for the window-high. (investors.csg.com)
Valuation argues for rebound potential, but not for a full reset to the IPO highs on this short horizon. Third-party consensus pages showed an average 12-month analyst target around €35.4-€35.6 from 10-13 analysts, far above the current market price. Separately, a State Street factsheet for a European defence basket showed a FY1 P/E of 32.82 as of 30 April 2026. Those are not apples-to-apples valuation anchors for CSG, especially after a credibility shock, but they do show that the stock has room to bounce hard if the upcoming updates substantially validate management’s case. (investing.com)
I also modestly discount the risk of a classic IPO lock-up overhang crushing the stock during the target window. The prospectus snippet indicates restrictions on the company’s ability to issue, sell, or transfer shares for 180 days after settlement, while lock-up deeds on relevant holders run for 360 days. Since the IPO represented only 15.2% of issued share capital, the float is still limited enough to make the stock jumpy, but the longer holder lock-up makes a large selling-shareholder dump during July-August less likely than in a plain-vanilla 180-day IPO structure. That limited float cuts both ways: it increases squeeze risk on good news and air-pocket risk on bad news. (investors.csg.com)
My forecasting model is therefore a four-scenario mixture for the highest close during the 1 July-7 August window, not for the end-of-window close. Bear case, 28%: Hunterbrook-style concerns continue to dominate, Q1 or H1 disappoints, and the window-high is centered near €15.5. Base case, 42%: results are good enough to stabilize sentiment and permit a partial retracement, with the window-high centered near €21.0. Bull case, 22%: Q1 plus continued contract flow and sector support produce a stronger re-rating, with the window-high centered near €26.8. Squeeze/re-rating tail, 8%: low float plus strong execution and relief from the allegations push the window-high into the low-to-mid €30s, centered near €34.5. I used lognormal noise with 11-13% log-scale dispersion within each scenario to reflect the very high observed volatility since listing. This yields a median around €21.2, mean around €22.1, roughly a 23% chance the window-high stays below €17, about a 26% chance it exceeds €25, and about an 11% chance it exceeds €30.
My bottom line is that the most likely highest official close is in the low €20s, with the modal region around €21-22. I think the market is now applying a large credibility discount, but the combination of still-strong reported backlog and guidance, a Q1 update before the window, H1 results on the final resolution day, and a small effective float makes a partial rebound more likely than a continued straight-line collapse. I keep a meaningful bear tail because the short thesis attacked exactly the issues that tend to keep valuation discounts in place: production capacity, governance, and the quality of disclosures. (live.euronext.com)
CSG listed on Euronext Amsterdam on January 23, 2026 at €25 per share, with Euronext describing the IPO as implying a €25 billion market capitalization. In its full-year 2025 results, the company reported €6.7 billion of revenue, €1.6 billion of adjusted operating EBIT, €15 billion of backlog and a €27 billion pipeline, and it reaffirmed FY2026 guidance for €7.4-7.6 billion of revenue with adjusted operating EBIT margin of about 24-25%. (live.euronext.com)
The key fact for this forecast is that the market has stopped treating CSG as a straightforward defence-growth story and is now applying a large credibility discount. Reuters reported that on May 4, 2026, the shares closed down 13.1% after the Hunterbrook short report, after falling as much as 26% intraday, and that the stock was already down more than 50% from the IPO. As of May 11, 2026, MarketScreener showed CSG at €15.39 intraday; the most recent official closes listed there were €15.91 on May 5, €17.06 on May 6, €16.15 on May 7 and €15.78 on May 8. MarketScreener also showed a one-month range of €13.62 to €22.83 and a 2026 range of €13.62 to €35.50. (ca.marketscreener.com)
The company has publicly rejected the short-seller allegations, said its disclosures were accurate, said the order book remains strong, and said it would provide a further update with Q1 results on May 20, 2026. The March 26 results statement also said IPO-related costs would be reflected in Q1 2026, and the available MarketScreener company calendar shows May 20, 2026 as the next listed earnings release. (live.euronext.com)
Valuation pulls the forecast upward, but not all the way back to the pre-collapse narrative. MarketScreener showed CSG on May 11 at about 14.8x 2026 estimated earnings and 2.29x 2026 EV/sales, with analyst estimates of roughly €7.55 billion sales and €1.07 billion net income for 2026. Separately, MarketScreener showed 9 analysts with an average target price of €35.55. That says a lot of bad news is already in the stock, but I heavily haircut those targets because analyst targets often lag fast-moving governance controversies and because the market is still deciding how much of the Hunterbrook critique is noise versus signal. (marketscreener.com)
Sector context is mixed rather than uniformly bullish. Reuters reported on April 20, 2026 that investors had cooled on European defence stocks as profit-taking and stretched valuations collided with uncertainty over the future mix of warfare; Reuters also noted that the MSCI Europe Aerospace and Defence Index fell 9.2% in March, its biggest monthly drop in five years, even as fund flows into the WisdomTree Europe Defence ETF remained positive. So there is still a structural defence-spending bull case, but not the kind of momentum backdrop that makes a quick return to January-February exuberance the default outcome. (investing.com)
My synthesis is: the fundamentals and consensus estimates argue CSG should trade higher than the current mid-teens if May 20 substantially reassures the market; the governance and production-capacity controversy, plus the broader sector cooldown, make a full recovery toward the analyst target or a sustained move back above €30 by July-August unlikely; and because the question asks for the highest close over a multi-week window rather than a single close, the resolution value should sit above my expected typical day in that window. My resulting distribution has a median around €19.2, an interquartile range of about €16.0 to €22.7, roughly a 14% chance of at least €25, and about a 5% chance of above €30. (marketscreener.com)
I anchor on the latest completed close I could verify in the fetched historical data: €15.78 on 8 May 2026. CSG listed at €25 on 23 January 2026, Reuters reported that the shares closed 31% above IPO price on debut, and Reuters also reported that by 4 May 2026 the stock had fallen by more than 50% from the IPO after a Hunterbrook short report triggered a 13.1% one-day drop. The daily history shows why the distribution must stay wide: closes above €30 were still seen in early March, while repeated daily moves of roughly 5-10% have been common. Only 15.2% of issued share capital was floated post-settlement, which likely adds to volatility. (stockanalysis.com)
Fundamentals are still strong enough to support a rebound. CSG reported FY2025 revenue of €6.741 billion, adjusted operating EBIT of €1.626 billion, order backlog of €15 billion, FY2026 revenue guidance of €7.4-7.6 billion, and an adjusted operating EBIT margin target of about 24-25%. CSG also said its 2025 own-production capacity was about 630,000 rounds, guided to about 20% growth in own production in 2026, and said the €275 million related-party receivable had been settled in full in Q1 2026. Moody’s upgraded the backed senior secured debt rating to Baa3 while Fitch affirmed BBB- with a stable outlook. (live.euronext.com)
But the market clearly does not treat this as a plain-vanilla growth story. The stock fell sharply around the 26-27 March FY2025 release even though guidance was reaffirmed, which I read as evidence that investors were already worried about execution, working capital, leverage and disclosure quality before the Hunterbrook report. Reuters also reported in April that European defence shares had cooled as investors reassessed stretched valuations. So I do not assume that good long-run demand automatically translates into a near-term re-rating for CSG. (stockanalysis.com)
The resolution window itself is catalyst-heavy. CSG’s Q1 2026 trading update is scheduled for 20 May 2026 and Half Year 2026 Results for 7 August 2026, the final day in the resolution window; that makes a sharp move on the last day a real possibility. The investor calendar also shows a quiet period from 8 July 2026, which may reduce the odds of many fresh positive disclosures during most of the window. IPO documents say settlement was expected on 27 January 2026; the company’s 180-day lock-up therefore expires around 26 July 2026, but the selling shareholder and certain directors are locked for 360 days, so there is no classic broad insider unlock during the window. Meanwhile, the broader demand backdrop for European defence remains supportive because the EU and member states continue to push Readiness 2030 and higher defence spending. (investors.csg.com)
I therefore model the maximum closing price directly as a four-scenario mixture: 15% continued de-rating/controversy drag, 40% depressed stabilization, 30% partial recovery after Q1/H1 reassurance, and 15% strong vindication plus sector-rally/short-squeeze behavior. I center those scenarios around maxima of roughly €11-12, €15-16, €19-20 and €25 respectively, with lognormal tails to preserve the possibility of both a deeper washout and a rebound into the high 20s.
That gives a median forecast of about €17.1 and a mean around €17.7. My rough 80% interval is about €12.0 to €24.3; the probability of finishing the window with a maximum close above €30 is only about 2%, but not zero because CSG has already traded above €30 this year and the free float is relatively small. Overall, I expect the window high to land modestly above the recent €15.78 close, but well below the €25 IPO price unless the 7 August results decisively rebuild trust. (stockanalysis.com)